Metformin in Pre-diabetes Patients and Stroke study

INTERVENTION: Metformin XR starting at 500mg daily and increase to a total daily dose of 1500mg daily after 1 month from intervention (If the dose of Metformin XR 500mg daily was tolerated at the one month follow up phone call, the dose will be tripled from 500mg daily to 1500mg daily. ) Intervention will commence within 6 week from stroke The administartion is oral tablet The duration of administartion will be 4 months Compliance will check by counting the remaining tablets at 1 month and over 2.5 months from intervention over follow up phone calls CONDITION: Pre‐diabetes Stroke PRIMARY OUTCOME: Safety and tolerability of Metformin XR assessed by using a validated side effects questionnaire ; (Pereira DI, Couto Irving SS, Lomer MC, Powell JJ. A rapid, simple questionnaire to assess gastrointestinal symptoms after oral ferrous sulphate supplementation. BMC Gastroenterol. 2014 Jun 4;14:103. ) ; SECONDARY OUTCOME: C‐peptide using ECLIA method HbA1c levels measured in fasted blood samples using immunoassay method blood pressure using digital blood pressure monitoring body mass index calculated as weight /( height)2 fasting glucose levels measured using Hexokinase fasting lipid profile using enzymatic colorimetric method urine albumin to creatinine ratio. Urea measured using Urease/GLDH and Creatinin by using Jaffe reaction method waist circumference measured as the abdominal circumference just above the iliac crest in a standing and relaxed position INCLUSION CRITERIA: Age more than 18 years Had an ischaemic stroke or TIA who are stable at least with a 6 week period following stroke Modified Rankin Scale less than or equal to 3 HbA1c levels 5.7 to 6.4%